Form 4: Kodiak Sciences CFO Granted Stock Options
SEC Form 4 Filing
John A. Borgeson, CFO of Kodiak Sciences, was granted stock options for 334,500 shares on August 5, 2024, vesting monthly over four years.
Summary
- John A. Borgeson, the Executive Vice President and Chief Financial Officer of Kodiak Sciences Inc., was granted stock options on August 5, 2024.
- The options are for 334,500 shares of Kodiak Sciences' common stock.
- The exercise price of the options is $2.49 per share.
- The options vest monthly, with one-forty-eighth vesting one month after July 1, 2024, and the remainder vesting in 47 successive equal monthly installments, contingent upon continuous service.
- The options expire on August 4, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and the company's future.
Positives
- The granting of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment and performance.
Future Outlook
The vesting schedule suggests an expectation of continued service and contribution from the CFO over the next four years.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders. The size of the grant and the vesting schedule are typical for executive compensation packages in similar companies.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation in the biotech industry.
- Companies like Regeneron, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation packages.
- The vesting schedule of one-forty-eighth per month is a common vesting structure, similar to what is seen at companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a sign of stability and investment in leadership.
Key Dates
| Date | Description |
|---|---|
| July 1, 2024 | Start date for vesting schedule (one month prior to the first vesting date). |
| August 5, 2024 | Date of the stock option grant. |
| August 7, 2024 | Date of the Form 4 filing. |
| August 4, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.